The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Improving survival for people with HIV has brought management of co-morbidities into focus. In the era of highly active antiretroviral therapy, co-infection with either hepatitis B virus and/or hepatitis C virus, and HIV therapies themselves, have increased liver disease-related morbidity and mortality. The dual anti-HIV and anti-hepatitis B activity of several established and emerging therapeutic agents provides the opportunity to both restore immune function and prevent liver disease progression in people with HIV-hepatitis B virus co-infection. Improving hepatitis C antiviral therapy also provides optimism around management of liver disease in people with HIV-hepatitis C virus co-infection. However, formulation of appropriate therapeutic strategies for HIV-hepatitis B and HIV-hepatitis C co-infection requires further research, including clinical trials of combination antiviral therapy with specific anti-hepatitis B and anti-hepatitis C activity. A possible role may also exist for combined antiviral and immune-based therapies.
Dore
G J
GJ
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Australia. gdore@nchecr.unsw.edu.au
Cooper
D A
DA
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006509:Hepatitis B / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D012254:Ribavirin / Q000627:therapeutic use; D014766:Viremia / Q000188:drug therapy
D019259:Lamivudine; D012254:Ribavirin